Therapeutic indications, systemic associations and outcomes of mycophenolate mofetil use in patients with sight-threatening ocular inflammation

Poster Details

First Author: A.Elsahn UK

Co Author(s):    P. Kumar                             

Abstract Details


To assess the indications and outcomes of Mycophenolate Mofetil use in patients with severe ocular inflammation in a tertiary-referral uveitis service.


Retrospective analysis of medical notes at the uveitis service of Leicester Royal Infirmary.


All patients on mycophenolate mofetil for ocular inflammation in our uveitis service were identified and their medical notes were retrospectively reviewed. Presenting LogMAR visual acuity (VA), final VA, laterality, duration of follow up, associated systemic diseases and ocular complications were recorded.


Sixty-seven eyes of 40 patients were identified in our electronic database, 25 females and 15 males, with a mean age of 47.25 years (SD ± 14.83, range 18 – 81). Mean duration of follow up was 74.5 months (SD ± 86.4, range 1 - 383). Mean presenting VA was +0.28 (SD ± 0.43, range -0.10 - +1.78 to) and mean final VA was 0.40 (SD ± 0.44, range 0.00 - +1.78). Diagnoses of ocular inflammation included scleritis (9 patients), idiopathic intermediate uveitis (7 patients), recurrent/chronic anterior uveitis (5 patients), birdshot chorioretinopathy (3 patients), sarcoid-related uveitis (3 patients), idiopathic panuveitis (3 patients), Vogt-Koyanagi-Harada disease (3 patients), punctate inner choroidopathy (3 patients), idiopathic orbital inflammation (1 patient), systemic lupus erythematosus (1 patient), Behçet's disease (1 patient) and Tubulointerstitial Nephritis and Uveitis Syndrome (1 patient). Systemic associations included sarcoidosis, psoriasis, Reiter syndrome, systemic lupus erythematosus, granulomatosis with polyangiitis, polychondritis and rheumatoid arthritis.


Mycophenolate Mofetil can be very beneficial in managing patients with severe, sight-threatening ocular inflammation, potentially reducing ocular morbidity and mortality associated with systemic autoimmune states. All patients on immune-modulatory therapy must be monitored closely for the potentially serious side-effects

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy